18 Future Directions for Nephrotic Syndrome Therapies in 2026
The year 2026 is witnessing the first clinical applications of CAR-T cell therapy for severe, refractory autoimmune kidney disease. By engineering a patient's own T-cells to specifically target the B-cells producing PLA2R antibodies, researchers are achieving complete immunological cures in patients who failed all other nephrotic syndrome therapies. While currently reserved for extreme cases,...
0 Commentaires
0 Parts
358 Vue